Some shoulder symptoms need prompt care first

A serious injury needs urgent care

If one shoulder looks clearly different after a fall, seek urgent care. Sudden weakness may mean a torn rotator cuff, the four muscles and tendons holding the shoulder ball steady. Hand numbness or weakness may begin in your neck instead. I'd rather get those new problems checked early.

Seek emergency help if chest pressure comes with shoulder soreness. Sweating, nausea, or jaw soreness adds more reason for concern. Don't drive to a regular shoulder appointment with those symptoms. The first visit must rule out danger, not discuss a planned treatment such as PRP.

A scan alone doesn't decide your care

Wear in those four shoulder tendons often appears even without soreness. Ask how the scan fits the arm's strength, movement, and painful tasks. If the arm still works well, there may be time for simpler care. New weakness after a fall or hard pull needs a quicker response.

For a regular visit, note the tasks that you can no longer do. Take along your scan and a current list of medicines. Ask for the full cost and visit count before agreeing to any care. After urgent causes are ruled out, QC Kinetix medical providers can examine your shoulder and discuss non-surgical regenerative treatments, including PRP made from blood.

Sources

1. In a nationally representative Finnish population sample of 602 adults aged 41-76 who had bilateral 3-Tesla shoulder MRI regardless of symptoms, rotator cuff abnormalities were found in 98.7% of participants (25% tendinopathy, 62% partial-thickness tear, 11% full-thickness tear). Abnormalities were present in 96% of ASYMPTOMATIC shoulders. Only full-thickness tears were more common in symptomatic shoulders, and that difference all but disappeared after adjustment (absolute difference 0.8%, 95% CI -3.4% to 6.0%).

   Ibounig T, et al. — Incidental Rotator Cuff Abnormalities on Magnetic Resonance Imaging.. JAMA Intern Med, 2026. DOI: 10.1001/jamainternmed.2025.7903.

2. In the MOON Shoulder prospective cohort of 452 patients with symptomatic, ATRAUMATIC full-thickness rotator cuff tears, physical therapy succeeded in more than 70% of patients at 10 years: only 115 (27.0%) had surgery at any point over the decade. Patient-reported outcomes improved with physical therapy and did NOT decline over 10 years in those who never had surgery. The strongest predictor of early surgery was low patient expectation of physical therapy, not tear anatomy.

   Kuhn JE, et al. — The Predictors of Surgery for Symptomatic, Atraumatic Full-Thickness Rotator Cuff Tears Change Over Time: Ten-Year Outcomes of the MOON Shoulder Prospective Cohort.. J Bone Joint Surg Am, 2024. DOI: 10.2106/JBJS.23.00978.

3. Semi-structured interviews with 25 academic specialists - cardiology, ophthalmology, ORTHOPEDICS, pulmonology and neurology - on how they counsel patients asking about experimental stem cell and regenerative interventions. Orthopedists relied most heavily on informational approaches: explaining the science, sharing risks, providing principles. Reported challenges included wanting to support a patient's decision while worrying about harms, and addressing stem cell hype and unrealistic expectations.

   Smith C, et al. — Academic Physician Specialists' Approaches to Counseling Patients Interested in Unproven Stem Cell and Regenerative Therapies-A Qualitative Analysis.. Mayo Clinic proceedings, 2021. DOI: 10.1016/j.mayocp.2021.06.026.

4. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.